Drug-drug Interactions in Patients with HIV and Cancer in Sub-Saharan Africa
| Autor: | Prabha Chandrasekaran, Elad Sharon, William D. Figg, Sarah E Lochrin, Robert Yarchoan, Tristan M. Sissung, Douglas K. Price, Thomas S. Uldrick, Ravie Kem, Jonathan D. Strope |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
media_common.quotation_subject Population HIV Infections Drug resistance Bioinformatics Essential medicines chemistry.chemical_compound Pharmacokinetics Neoplasms Humans Medicine Drug Interactions Pharmacology (medical) education Africa South of the Sahara media_common Polypharmacy education.field_of_study business.industry General Medicine Drug interaction Infectious Diseases Pharmaceutical Preparations chemistry Dolutegravir business |
| Zdroj: | Aids Reviews. 23 |
| ISSN: | 1139-6121 |
| DOI: | 10.24875/aidsrev.20000005 |
| Popis: | In Sub-Saharan Africa, the cancer burden is predicted to increase by > 85% by 2030, the largest increase worldwide. This region has a large HIV-positive population. Drug-drug interactions (DDIs) from concomitant use of multiple drugs increase the risk of drug toxicities, sub-optimal therapy, and drug resistance. With the increase in polypharmacy, involving antiretroviral (ARV), and anticancer drugs, there is a greater need for an appreciation of clinically relevant DDIs. Anticancer and ARV drugs studied in this review were from The World Health Organization's Model List of Essential Medicines 2017. We reviewed; drug package inserts, www.drugbank.ca and www.UpToDate.com, to evaluate pharmacokinetic interactions with cytochrome P450 (CYP450) and ABCB1. The DDIs between drugs were assessed using the University Of Liverpool, UK HIV Drug Interactions Checker, and the LexiComp Drug Interaction tool of www.UpToDate.com. About 70% of ARVs studied interact with CYP450, all involve CYP3A4, and 55% interact with ABCB1. About 65% of anticancer drugs interact with CYP450, 44% of which do so through CYP3A4. About 75% of anticancer drugs interact with ARV drugs, with nine absolute contraindications to concomitant therapy. There exist a substantial number of DDIs between ARV and anticancer drugs, primarily mediated through CYP450 enzymes. Dolutegravir based regimens offer the safest DDI profile for concurrent use with anticancer drugs. However, there are substantial gaps in our knowledge, and this study serves to highlight the need for additional research to better define these interactions and their effect on drug exposure, as attention to these DDIs is a relatively simple intervention that could lead to optimizing disease treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|